CattlePost.com Now Free for Customers of IGENITY®

Web site provides one-stop-shopping for cattle profiled with IGENITY

DULUTH, Ga. — February 4, 2010 — IGENITY® — a division of Merial — and Global Animal Management (GAM) announce that customers of IGENITY can now post information about upcoming sales on www.CattlePost.com, giving buyers access to information about sales featuring cattle profiled with IGENITY — all in one place, free of charge.

“The demand for cattle profiled with IGENITY is unprecedented,” says Dr. Kevin DeHaan, technical services director, IGENITY. “Commercial producers understand they can’t afford to buy cattle without all of the information available, and seedstock producers are meeting this demand by providing the comprehensive IGENITY profile on sale cattle. Now, both can connect on one Web site, free.”

Jim Heinle, president, GAM, says CattlePost.com has helped producers market their Tri-Merit® cattle and now can help producers market cattle profiled with IGENITY.

“Whether they are looking for source- and age-verified cattle or those with a comprehensive DNA profile, producers have raised the bar by demanding cattle with more information,” he says. “Now, producers have access to the cattle they want on one Web site — CattlePost.com.”

To post information on CattlePost.com, customers of IGENITY can log in with the same username and password they use for the IGENITY Web site. Angus breeders who have gained genomic-enhanced EPDs from Angus Genetics Inc.® (AGI) and IGENITY can log into the site with their AGI barcode number and ZIP code.

Dr. DeHaan says helping producers market their profiled cattle is part of the commitment IGENITY has to providing user-friendly DNA technology solutions.

“IGENITY offers the most comprehensive and powerful DNA profile available,” he says. “However, our commitment to producers doesn’t stop there. At IGENITY, we offer online software, a team of advisers and now free access to a Web site that can help producers add even more value to their cattle by promoting their use of the IGENITY profile.”

The comprehensive DNA offering from IGENITY includes analyses for 15 economically important traits; the only available DNA analyses for maternal and reproductive traits; the most complete list of carcass traits; the only feed efficiency analyses for both Bos indicus and Bos taurus cattle; and more.1 IGENITY also offers user-friendly information management software and expert consultation to help producers customize this advanced information to their individual herd goals.

GAM offers products, solutions and services for animal identification, data storage, processing, analysis and reporting that add value to individuals or groups of cattle. GAM was the first company to have a USDA-interim-approved identification database with electronic ear tags approved by the National Animal Identification System (NAIS). In addition, GAM’s Tri-Merit is USDA Process Verified Program (PVP) approved for source and age verification and as a data service provider. Tri-Merit is also an approved Animal Tracking Database (ATD) for NAIS and is Country of Origin Labeling (COOL) compliant.

For more information about IGENITY, producers should contact their IGENITY sales representative, call (877) 443-6489 or visit www.igenity.com/beef. For more information about GAM or Tri-Merit, call 1 (800) 235-9824 or visit www.tri-merit.com.

IGENITY is a division of Merial. Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,700 people and operates in more than 150 countries worldwide. Its 2009 sales were $2.6 billion. Merial is the Animal Health subsidiary of sanofi-aventis. For more information, please see www.merial.com.

About Intervet/Schering-Plough Animal Health

Intervet/Schering-Plough Animal Health, based in Boxmeer, the Netherlands, is focused on the research, development, manufacturing and marketing of animal health products. The company offers customers one of the broadest, most innovative animal health portfolios, spanning products to support performance and to prevent, treat and control disease in all major farm and companion animal species. Intervet/Schering-Plough Animal Health is a fully owned business unit of Merck & Co., Inc., based in Whitehouse Station NJ, USA. For more information about Intervet/Schering-Plough Animal Health visit: www.intervet.com and www.merck.com.

About Merck

Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching programs that donate and deliver our products to the people who need them. Merck. Be Well. For more information, visit www.merck.com

Forward Looking Statement

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the proposed merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s and Schering-Plough’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period, due to, among other things, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2008 Annual Report on Form 10-K, Schering-Plough’s Quarterly Report on Form 10-Q for the quarterly period ended Sept. 30, 2009, the proxy statement filed by Merck on June 25, 2009 and each company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Sponsored Introduction Continue on to (or wait seconds) ×